Major study on DiagnoCure's GCC biomarker publish...( - Results demonstrate that GCC...),Health

         - Results demonstrate that GCC is the strongest independent
                 predictor of colorectal cancer recurrence -

    Ticker Symbol: CUR

QUEBEC CITY, QC and WEST CHESTER, PA, Feb. 17 /PRNewswire-FirstCall/ - The Journal of the American Medical Association (JAMA), Vol. 301, #7, this week published positive results from a major prospective 5-year multicenter study of over 400 enrolled patients demonstrating that guanylyl cyclase C (GCC) is the strongest independent predictor of colorectal cancer recurrence in patients considered low risk by current assessment methods. The study was conducted by investigators from Thomas Jefferson University, with contributions from McGill University, the Fox Chase Cancer Center and others. DiagnoCure Inc. owns the exclusive worldwide diagnostic rights to the GCC biomarker, and since last September has offered the Previstage(TM) GCC test to physicians and patients from its Pennsylvania-based service laboratory.

GCC is a gene coding for a protein which is expressed in colorectal cells, both normal and cancerous, but is never found in normal tissue in other parts of the body. When GCC is detected in lymph nodes removed during colorectal cancer surgery, it is an indication of the presence of colorectal cancer metastases.

The study's principal investigator, Dr. Scott Waldman, Chairman of the Department of Pharmacology and Experimental Therapeutics at Thomas Jefferson University, stated "Patients with cancer cells in their regional lymph nodes carry a worse prognosis and a higher risk of recurrence; detecting GCC in the patient lymph nodes could be useful for identifying patients who might benefit from treatment with adjuvant chemotherapy."

In a group of 257 colorectal cancer (CRC) patients who were thought to have a lower risk of recurrence according to histopathology (stage I and II patients), when GCC was considered independently
'/>"/>